Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 DOVU DOVU +48.16%
#3 Velvet Velvet +44.46%
#4 Akedo Akedo +40.57%
#5 Black Phoenix Black Phoenix +33.98%
#6 Cross Cross +24.15%
#7 Cap Cap +20.35%
#8 DoubleZero DoubleZero +14.60%
#9 Tutorial Tutorial +11.59%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.77%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Rank in Stocks #39467
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Share Price
$0.11725176
Last synced: 2025-07-14
Market Cap
$481.50K
Change (1 day)
-0.20%
Change (1 year)
0.00%
Country
FR
Trade PHAXIAM Therapeutics S.A. (PHXM)

Category

Healthcare
P/B ratio for PHAXIAM Therapeutics S.A. (PHXM)
P/B ratio as of August 2026 TTM: 0.02
According to PHAXIAM Therapeutics S.A. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0.02. At the end of 2022 the company had a P/B ratio of 0.48.
P/B ratio history for PHAXIAM Therapeutics S.A. from 2016 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) 0.02 -97.64%
2023 0.78 60.84%
2022 0.48 -77.96%
2021 2.20 -55.37%
2020 4.93 250.70%
2019 1.40 82.40%
2018 0.77 -33.59%
2017 1.16 -62.33%
2016 3.08 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 33,928.80%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 34,401.63%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 19,650.00%
BE